Lower Extremity Muscle Strengthening Program in Myotonic Dystrophy Type 1 from Groupe de recherche interdisciplinaire sur les maladies neuromusculaires
Myotonic dystrophy (DM1) is a rare hereditary disease that presents with several clinical manifestations including muscle weakness, apathy and fatigue. Currently it is only possible to treat the symptoms of the disease and not the disease itself. To help address the symptoms experienced by people with DM1, the Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN) developed a muscle strengthening program which has led to significant gains in muscle strength, functional capacity, decreased apathy and reduced fatigue (1,2,3).
GRIMN recently created a video aimed at health professionals that provides an in-depth explanation of the DM1 training parameters used in their studies. This video presents a strength training program designed for individuals with DM1
This resource is primarily intended for healthcare professionals working with the DM1 population, particularly physiotherapists who are most directly involved in implementing strength training interventions. It is also relevant for individuals living with DM1, who are encouraged to present it to their healthcare providers.
The video is available in both English and French on the GRIMN web page.
- Gallais, M. P. Roussel, L. Laberge, L. J. Hebert, E. Duchesne, Impact of a 12-week Strength Training Program on Fatigue, Daytime Sleepiness, and Apathy in Men with Myotonic Dystrophy Type 1. J Neuromuscul Dis 9, 629-639 (2022).
- Girard-Cote et al., Resistance training in women with myotonic dystrophy type 1: a multisystemic therapeutic avenue. Neuromuscul Disord 40, 38-51 (2024).
- P. Roussel, L. J. Hebert, E. Duchesne, Strength-training effectively alleviates skeletal muscle impairments in myotonic dystrophy type 1. Neuromuscul Disord 30, 283-293 (2020).
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.